Trials / Recruiting
RecruitingNCT06720766
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- The Third People's Hospital of Chengdu · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | FibbroScan and biopsy | In individuals with obesity, a biopsy is performed within a week after undergoing an FibroScan examination. |
Timeline
- Start date
- 2023-10-24
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2024-12-06
- Last updated
- 2024-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06720766. Inclusion in this directory is not an endorsement.